Vincristine, actinomycin, and cyclophosphamide compared with vincristine, actinomycin, and cyclophosphamide alternating with vincristine, topotecan, and cyclophosphamide for intermediate-risk rhabdomyosarcoma: children's oncology group study D9803.
about
Children's Oncology Group's 2013 blueprint for research: Soft tissue sarcomasThe novel tubulin polymerization inhibitor MHPT exhibits selective anti-tumor activity against rhabdomyosarcoma in vitro and in vivoEmbryonic signaling pathways and rhabdomyosarcoma: contributions to cancer development and opportunities for therapeutic targetingPatterns of chemotherapy-induced toxicities in younger children and adolescents with rhabdomyosarcoma: a report from the Children's Oncology Group Soft Tissue Sarcoma CommitteeRhabdomyosarcoma: review of the Children's Oncology Group (COG) Soft-Tissue Sarcoma Committee experience and rationale for current COG studiesRhabdomyosarcoma in adolescent and young adult patients: current perspectives.Local failure in parameningeal rhabdomyosarcoma correlates with poor response to induction chemotherapy.Pediatric Rhabdomyosarcoma.Generation of novel patient-derived CIC- DUX4 sarcoma xenografts and cell lines.What is new in the biology and treatment of pediatric rhabdomyosarcoma?Undifferentiated sarcoma of the liver: a single institution experience using a uniform treatment approach.Early treatment failure in intermediate-risk rhabdomyosarcoma: results from IRS-IV and D9803--a report from the Children's Oncology Group.Randomized phase II window trial of two schedules of irinotecan with vincristine in patients with first relapse or progression of rhabdomyosarcoma: a report from the Children's Oncology Group.Age-related toxicity in patients with rhabdomyosarcoma: a report from the children's oncology group.Preliminary results of a phase II trial of proton radiotherapy for pediatric rhabdomyosarcoma.Histology, Fusion Status, and Outcome in Alveolar Rhabdomyosarcoma With Low-Risk Clinical Features: A Report From the Children's Oncology Group.A dosimetric comparison of proton and intensity modulated radiation therapy in pediatric rhabdomyosarcoma patients enrolled on a prospective phase II proton study.Tumor volume and patient weight as predictors of outcome in children with intermediate risk rhabdomyosarcoma: a report from the Children's Oncology Group.GLI inhibitor GANT-61 diminishes embryonal and alveolar rhabdomyosarcoma growth by inhibiting Shh/AKT-mTOR axisTreatment results for patients with localized, completely resected (Group I) alveolar rhabdomyosarcoma on Intergroup Rhabdomyosarcoma Study Group (IRSG) protocols III and IV, 1984-1997: a report from the Children's Oncology GroupRhabdomyosarcoma in infants younger than 1 year: a report from the Children's Oncology Group.Effect of radiotherapy techniques (IMRT vs. 3D-CRT) on outcome in patients with intermediate-risk rhabdomyosarcoma enrolled in COG D9803--a report from the Children's Oncology Group.Rhabdomyosarcoma of the head and neck in childrenDelayed primary excision with subsequent modification of radiotherapy dose for intermediate-risk rhabdomyosarcoma: a report from the Children's Oncology Group Soft Tissue Sarcoma Committee.Proton radiotherapy for parameningeal rhabdomyosarcoma: clinical outcomes and late effects.The effect of radiation timing on patients with high-risk features of parameningeal rhabdomyosarcoma: an analysis of IRS-IV and D9803.Trial watch: Chemotherapy with immunogenic cell death inducersClinical Application of Prognostic Gene Expression Signature in Fusion Gene-Negative Rhabdomyosarcoma: A Report from the Children's Oncology GroupDense pattern of embryonal rhabdomyosarcoma, a lesion easily confused with alveolar rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology GroupPAX-FOXO1 fusion status drives unfavorable outcome for children with rhabdomyosarcoma: a children's oncology group report.Local control and outcome in children with localized vaginal rhabdomyosarcoma: a report from the Soft Tissue Sarcoma committee of the Children's Oncology Group.A Patient-Derived Xenograft Model of Parameningeal Embryonal Rhabdomyosarcoma for Preclinical Studies.Two Cases of Adolescents with Paratesticular Rhabdomyosarcoma Inadequately Treated: The Problem of Referral.From fighting depression to conquering tumors: a novel tricyclic thiazepine compound as a tubulin polymerization inhibitorOutcome of Rhabdomyosarcoma in First Year of Life: Children's Cancer Hospital 57357 Egypt.Histologic and clinical characteristics can guide staging evaluations for children and adolescents with rhabdomyosarcoma: a report from the Children's Oncology Group Soft Tissue Sarcoma Committee.Prognostic Factors for Outcome in Localized Extremity Rhabdomyosarcoma. Pooled Analysis from Four International Cooperative Groups.Intensive Multiagent Therapy, Including Dose-Compressed Cycles of Ifosfamide/Etoposide and Vincristine/Doxorubicin/Cyclophosphamide, Irinotecan, and Radiation, in Patients With High-Risk Rhabdomyosarcoma: A Report From the Children's Oncology Group.Parameningeal rhabdomyosarcoma in pediatric age: results of a pooled analysis from North American and European cooperative groups.Local Control for Intermediate-Risk Rhabdomyosarcoma: Results From D9803 According to Histology, Group, Site, and Size: A Report From the Children's Oncology Group
P2860
Q26825000-AB662352-CFD9-4A5C-BEA8-DF0D749ED7D4Q28545041-2D1ABFBB-B159-44E6-A5C8-3FBA9DC4AC0CQ30426842-02974DC5-9FBB-4B8E-95FB-F03762656DB7Q33396263-F8C85094-0C3D-46E4-9864-96AD681648E1Q33559468-9E069C75-09E4-4019-B9B8-402CB6F9E7E4Q33800135-D3E1C28F-9FE0-4CE5-81E3-88C8C84AD579Q33821612-B415C4ED-B081-4A67-B520-7192CF57B912Q33842070-88B8EABB-905D-49C6-9B25-8A8DE7E012D3Q33875284-BF537D64-F2BA-4966-8288-5B6F1495CD04Q33895506-60A65DB2-1DAF-412D-9920-DCBA5231A239Q34040069-D5DFF446-8964-4AEC-862D-9599070A76ECQ34193980-4B3276EE-DF91-4686-9603-3629AE0D75BDQ34281235-A4018A71-4E8E-4C5A-8F6C-D98BFFB1AC35Q34381149-A06DA225-1C13-4B5F-BA3F-AD7EA98B700FQ34484192-CF1C9439-497C-4253-947D-351B37E70405Q34508636-49836F52-5270-414A-BE14-774BD26C5B3CQ34984155-D02E41DE-4EEC-4878-96BF-F377D8179C5DQ35051029-39F16CC8-AEE2-4124-B46D-5CF99CAB05A1Q35067950-DADDAA04-3ACC-44FE-8BF6-905906805675Q35084182-E9441922-23DD-47A8-A7E7-F5FDC284F887Q35119012-4B725BDA-A73F-4F6C-A78E-1AD3268BC7D1Q35161100-EAFADE7B-2B45-4DB6-B978-1334EB1FB9BAQ35648994-775599BF-3B18-4F4F-BC39-DE19FA1D2FCDQ35760674-E7B21CF3-DD71-4DEA-895E-18088EC9C937Q35792061-2BFF2FE6-917C-4AB9-B43D-EE49257CF279Q35914632-4D0A0EBB-98D8-4AC2-BA2E-6D48746DAD01Q36038456-30A046E2-ED7A-4CD8-B38A-8012EAA056C3Q36175120-A8139F9A-39C1-45B0-8299-EF0141D8D839Q36219115-D0E4823E-CA94-4B0F-AB82-E1A923793BD5Q36283044-737DB0BA-E471-40B8-AEC9-CF9B0D2AD6D9Q36284400-66A2BD6F-B075-4043-AD8D-9CFE4930DD16Q36367000-E52E5E4C-4E68-4B9F-A37E-2D8CD49B5067Q36753647-2A42F70B-F760-469E-8236-91B834CF5F42Q36775000-8C5FB8E4-F0AD-44CE-B495-330888AF2D63Q37101239-660025C3-BD53-44D9-B5BE-53BF237613F4Q37132373-360FD0B1-6FA9-4C8B-9F57-F402634F9D2FQ37212341-0AE8BE25-08F5-4734-847B-383B5362F9F5Q37350775-DA035DE6-0156-405A-9AE6-A7BA8ADE9660Q37404111-7CE21880-6E19-45C6-AECB-93F23E894680Q37489203-9CE163E5-B22F-4B04-B1CF-3E9F645DAE05
P2860
Vincristine, actinomycin, and cyclophosphamide compared with vincristine, actinomycin, and cyclophosphamide alternating with vincristine, topotecan, and cyclophosphamide for intermediate-risk rhabdomyosarcoma: children's oncology group study D9803.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 21 September 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Vincristine, actinomycin, and ...... 's oncology group study D9803.
@en
Vincristine, actinomycin, and ...... 's oncology group study D9803.
@nl
type
label
Vincristine, actinomycin, and ...... 's oncology group study D9803.
@en
Vincristine, actinomycin, and ...... 's oncology group study D9803.
@nl
prefLabel
Vincristine, actinomycin, and ...... 's oncology group study D9803.
@en
Vincristine, actinomycin, and ...... 's oncology group study D9803.
@nl
P2093
P2860
P356
P1476
Vincristine, actinomycin, and ...... 's oncology group study D9803.
@en
P2093
Andrea A Hayes-Jordan
Carola A S Arndt
Charles N Paidas
David A Rodeberg
David M Parham
Douglas S Hawkins
James R Anderson
John C Breneman
Julie A Stoner
Lisa A Teot
P2860
P304
P356
10.1200/JCO.2009.22.3768
P407
P577
2009-09-21T00:00:00Z